Aquestive Therapeutics, Inc.
AQST
$4.06
$0.041.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -106.27% | -14.01% | 40.92% | -34.45% | -48.19% |
| Total Depreciation and Amortization | 12.23% | -0.71% | 0.72% | -18.24% | 6.92% |
| Total Amortization of Deferred Charges | 0.04% | 0.00% | -0.07% | 1.89% | 0.97% |
| Total Other Non-Cash Items | -51.54% | 52.60% | 11.88% | -32.32% | 48.13% |
| Change in Net Operating Assets | 764.87% | -413.17% | 118.41% | -194.47% | 209.35% |
| Cash from Operations | 33.05% | -59.83% | 66.18% | -260.61% | 45.38% |
| Capital Expenditure | 63.83% | -119.63% | 20.74% | -800.00% | 81.25% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 63.83% | -119.63% | 20.74% | -800.00% | 81.25% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 28.57% | 12.50% | -33.33% | -20.00% | 37.50% |
| Issuance of Common Stock | -99.16% | -- | -- | 12,614.29% | -12.95% |
| Repurchase of Common Stock | 74.29% | 18.60% | 87.77% | -70,200.00% | 99.50% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -20.00% | 0.00% | -- |
| Cash from Financing | -99.19% | 81,511.00% | -100.48% | 13,050.32% | 1,023.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -111.52% | 943.82% | -181.10% | 54.48% | 47.01% |